controlled drug such as Ibuprofen so as not to arouse a pharmacist's suspicion as to the legality of a controlled substance prescription and induce him to fill the prescription constitutes actionable misconduct under Factor Five. *See* 77 FR at 64141. Such conduct is, in essence, a form of subterfuge, and may threaten public health and safety by inducing a pharmacist into believing a controlled substance prescription is lawful rather than questioning its validity and refusing to fill it. *Cf.* 21 U.S.C. 843(a)(3) (''It shall be unlawful for any person knowingly or intentionally . . . to acquire or obtain possession of a controlled substance by misrepresentation, fraud, forgery, deception, or subterfuge.'').

Here, the evidence shows that at the UC's first visit, Respondent told him that she ''was gonna [sic] give you some ibuprofen. Because if you['re] filling in Florida which I encourage you to do so you're on the computer list. Then . . . for two reasons: Number one, the pharmacists usually want a non-prescription drug, a non-controlled substance drug rather . . . and ibuprofen is also good for inflammation.'' GE 7, at 6.

At his second visit, the UC told Respondent that a pharmacist refused to fill the Klonopin prescription she had issued previously. GE 9, at 9. Respondent advised the UC to take the prescription to another pharmacy and told him that it is not doctor-shopping if the pharmacist refused to fill the prescription; she also told the UC that she would ''write that [Klonopin] and I'll write another non-narcotic.'' *Id.* at 10. Respondent subsequently stated she would ''give [the UC] two small prescriptions'' for ibuprofen and ''one narcotic for each pharmacy that [he] might have to go to.'' *Id.* at 16. She added ''I want you to keep the extra ibuprofen so if they won't fill the Klonopin again you have another non-narcotic to use.'' *Id.* at 17.

In advising the UC how to avoid encountering difficulties in filling his prescriptions for controlled substances and in issuing non-narcotic prescriptions to minimize any suspicions by pharmacists, Respondent engaged in ''[s]uch other conduct which may threaten the public health and safety''). *See Perper,* 77 FR at 64141. *Cf. Nelson A. Smith,* 58 FR 65403, 65404 (1993) (holding that using strategies ''to avoid detection . . . such as falsifying patients charts and suggesting that the recipients of . . . illegal prescriptions go to different pharmacies'' is actionable misconduct under Factor Five).

I therefore hold that the Government's evidence with respect to Factors Two, Four, and Five establishes that Registrant ''has committed such acts as would render her registration . . . inconsistent with the public interest.'' 21 U.S.C. 824(a)(4). Because Respondent waived her right to a hearing (or to submit a written statement in lieu of a hearing), there is no evidence in the record to refute the conclusion that her continued registration is ''inconsistent with the public interest.'' *Id.* Accordingly, I will order that Respondent's registration be revoked and that any pending applications be denied.

## Order

Pursuant to the authority vested in me by 21 U.S.C. 823(f) and 824(a), as well as 28 CFR 0.100(b), I order that DEA Certificate of Registration No. AS1456361, issued to Marcia L. Sills, M.D., be, and it hereby is, revoked. I further order that any pending application of Marcia L. Sills to renew or modify the above registration, or any pending application of Marcia L. Sills for any other registration, be, and it hereby is, denied. This Order is effective September 5, 2017.

Dated: July 27, 2017.

**Chuck Rosenberg,**

*Acting Administrator.*

[FR Doc. 2017–16442 Filed 8–3–17; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

**[Docket No. DEA–470P]**

### Proposed Adjustments to the Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2017

**AGENCY:** Drug Enforcement Administration, Department of Justice.

**ACTION:** Notice with request for comments.

**SUMMARY:** The Drug Enforcement Administration (DEA) proposes to adjust the 2017 aggregate production quotas for several controlled substances in schedules I and II of the Controlled Substances Act and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

**DATES:** Interested persons may file written comments on this notice in accordance with 21 CFR 1303.13(c) and 1315.13(d). Electronic comments must be submitted, and written comments must be postmarked, on or before September 5, 2017. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.

Based on comments received in response to this notice, the Administrator may hold a public hearing on one or more issues raised. In the event the Administrator decides in his sole discretion to hold such a hearing, the Administrator will publish a notice of any such hearing in the **Federal Register**. After consideration of any comments or objections, or after a hearing, if one is held, the Administrator will publish in the **Federal Register** a final order establishing the 2017 adjusted aggregate production quotas for schedule I and II controlled substances, and an assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

**ADDRESSES:** To ensure proper handling of comments, please reference ''Docket No. DEA–470P'' on all correspondence, including any attachments. The Drug Enforcement Administration encourages that all comments be submitted electronically through the Federal eRulemaking Portal which provides the ability to type short comments directly into the comment field on the Web page or attach a file for lengthier comments. Please go to *http://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon completion of your submission you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on *Regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. Paper comments that duplicate electronic submissions are not necessary and are discouraged. Should you wish to mail a paper comment *in lieu* of an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

**FOR FURTHER INFORMATION CONTACT:** Michael J. Lewis, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152, Telephone: (202) 598–6812.

**SUPPLEMENTARY INFORMATION:**

**Posting of Public Comments**

Please note that all comments received in response to this docket are considered part of the public record. They will, unless reasonable cause is given, be made available by the Drug Enforcement Administration (DEA) for public inspection online at *http://www.regulations.gov.* Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter.

The Freedom of Information Act (FOIA) applies to all comments received. If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be made publicly available, you must include the phrase ''PERSONAL IDENTIFYING INFORMATION'' in the first paragraph of your comment. You must also place all the personal identifying information you do not want made publicly available in the first paragraph of your comment and identify what information you want redacted.

If you want to submit confidential business information as part of your comment, but do not want it to be made publicly available, you must include the phrase ''CONFIDENTIAL BUSINESS INFORMATION'' in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment.

Comments containing personal identifying information or confidential business information identified and located as directed above will generally be made available in redacted form. If a comment contains so much confidential business information or personal identifying information that it cannot be effectively redacted, all or part of that comment may not be made publicly available. Comments posted to *http://www.regulations.gov* may include any personal identifying information (such as name, address, and phone number) included in the text of your electronic submission that is not identified as directed above as confidential.

An electronic copy of this document is available at *http://www.regulations.gov* for easy reference.

**Legal Authority and Background**

Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of the DEA pursuant to 28 CFR 0.100.

The DEA established the 2017 aggregate production quotas for substances in schedules I and II and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine on October 5, 2016 (81 FR 69079). That notice stipulated that, in accordance with 21 CFR 1303.13 and 1315.13, all aggregate production quotas and assessments of annual need are subject to adjustment.

**Analysis for Proposed Adjusted 2017 Aggregate Production Quotas and Assessment of Annual Needs**

The DEA proposes to adjust the established 2017 aggregate production quotas and assessment of annual needs for certain schedule I and II controlled substances, and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, to be manufactured in the United States in 2017 to provide for the estimated medical, scientific, research, and industrial needs of the United States, for lawful export requirements, and for the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes.

In determining the proposed adjustment, the Acting Administrator has taken into account the criteria in accordance with 21 CFR 1303.13 (adjustment of aggregate production quotas for controlled substances) and 21 CFR 1315.13 (adjustment of the assessment of annual needs for ephedrine, pseudoephedrine, and phenylpropanolamine). The DEA determined whether to propose an adjustment of the aggregate production quotas and assessment of annual needs for 2017 by considering: (1) Changes in the demand for that class or chemical, changes in the national rate of net disposal of the class or chemical, and changes in the rate of net disposal of the class or chemical by registrants holding individual manufacturing quotas for the class; (2) whether any increased demand for that class or chemical, the national and/or individual rates of net disposal of that class or chemical are temporary, short term, or long term; (3) whether any increased demand for that class or chemical can be met through existing inventories, increased individual manufacturing quotas, or increased importation, without increasing the aggregate production quota; (4) whether any decreased demand for that class or chemical will result in excessive inventory accumulation by all persons registered to handle that class or chemical; and (5) other factors affecting medical, scientific, research, and industrial needs in the United States and lawful export requirements, as the Acting Administrator finds relevant. These quotas do not include imports of controlled substances for use in industrial processes.

The Acting Administrator also considered updated information obtained from 2016 year-end inventories, 2016 disposition data submitted by quota applicants, estimates of the medical needs of the United States, product development, and other information made available to the DEA after the initial aggregate production quotas and assessment of annual needs had been established. Other factors the Acting Administrator considered in calculating the aggregate production quotas, but not the assessment of annual needs, include product development requirements of both bulk and finished dosage form manufacturers, and other pertinent information. In determining the proposed adjusted 2017 assessment of annual needs, the DEA used the calculation methodology previously described in the 2010 and 2011 established assessment of annual needs (74 FR 60294, Nov. 20, 2009, and 75 FR 79407, Dec. 20, 2010, respectively).

The Acting Administrator, therefore, proposes that the year 2017 aggregate production quotas for the nine temporarily scheduled substances be established, and to adjust the 2017 aggregate production quotas for certain schedule I and II controlled substances and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:

| Basic class | Established 2017 quotas (g) | Proposed Revised 2017 quotas (g) |
|---|---|---|
| **Temporarily Scheduled Substances** | | |
| 4-Fluoroisobutyryl fentanyl | N/A | 30. |
| 5F–ADB; 5F–MDMB–PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate). | N/A | 30. |
| 5F–AMB (methyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-3-methylbutanoate) | N/A | 30. |
| 5F–APINACA; 5F–AKB48 (*N*-(adamantan-1-yl)-1-(5-fluoropentyl)-1*H*-indazole-3-carboxamide) | N/A | 30. |
| ADB–FUBINACA (*N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamide). | N/A | 30. |
| MDMB–CHMICA; MMB–CHMINACA (methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-carboxamido)-3,3-dimethylbutanoate). | N/A | 30. |
| MDMB–FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamido)-3,3-dimethylbutanoate) | N/A | 30. |
| Furanyl fentanyl | N/A | 30. |
| U–47700 | N/A | 30. |
| **Schedule I** | | |
| 1-(1-Phenylcyclohexyl)pyrrolidine | 10 | no change. |
| 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) | 30 | no change. |
| 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) | 30 | no change. |
| 1-[1-(2-Thienyl)cyclohexyl]piperidine | 15 | no change. |
| 1-Benzylpiperazine | 25 | no change. |
| 1-Methyl-4-phenyl-4-propionoxypiperidine | 2 | no change. |
| 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E) | 30 | no change. |
| 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D) | 30 | no change. |
| 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N) | 30 | no change. |
| 2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C–P) | 30 | no change. |
| 2-(2,5-Dimethoxyphenyl)ethanamine (2C–H) | 30 | no change. |
| 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B–NBOMe; 2C–B–NBOMe; 25B; Cimbi-36). | 25 | no change. |
| 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C) | 30 | no change. |
| 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C–NBOMe; 2C–C–NBOMe; 25C; Cimbi-82). | 25 | no change. |
| 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I) | 30 | no change. |
| 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I–NBOMe; 2C–I–NBOMe; 25I; Cimbi-5). | 5 | 30. |
| 2,5-Dimethoxy-4-ethylamphetamine (DOET) | 25 | no change. |
| 2,5-Dimethoxy-4-n-propylthiophenethylamine | 25 | no change. |
| 2,5-Dimethoxyamphetamine | 25 | no change. |
| 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2) | 30 | no change. |
| 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4) | 30 | no change. |
| 3,4,5-Trimethoxyamphetamine | 25 | no change. |
| 3,4-Methylenedioxyamphetamine (MDA) | 55 | no change. |
| 3,4-Methylenedioxymethamphetamine (MDMA) | 50 | no change. |
| 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) | 40 | no change. |
| 3,4-Methylenedioxy-N-methylcathinone (methylone) | 40 | no change. |
| 3,4-Methylenedioxypyrovalerone (MDPV) | 35 | no change. |
| 3–FMC; 3-Fluoro-N-methylcathinone | 25 | no change. |
| 3-Methylfentanyl | 2 | 30. |
| 3-Methylthiofentanyl | 2 | 30. |
| 4-Bromo-2,5-dimethoxyamphetamine (DOB) | 25 | no change. |
| 4-Bromo-2,5-dimethoxyphenethylamine (2–CB) | 25 | no change. |
| 4–FMC; Flephedrone | 25 | no change. |
| 4–MEC; 4-Methyl-N-ethylcathinone | 25 | no change. |
| 4-Methoxyamphetamine | 150 | no change. |
| 4-Methyl-2,5-dimethoxyamphetamine (DOM) | 25 | no change. |
| 4-Methylaminorex | 25 | no change. |
| 4-Methyl-N-methylcathinone (mephedrone) | 45 | no change. |
| 4-Methyl-$\alpha$-pyrrolidinopropiophenone (4-MePPP) | 25 | no change. |
| 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol | 50 | no change. |
| 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47,497 C8-homolog). | 40 | no change. |
| 5-Fluoro-PB–22; 5F–PB–22 | 20 | no change. |
| 5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1*H*-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone | 25 | no change. |
| 5-Methoxy-3,4-methylenedioxyamphetamine | 25 | no change. |
| 5-Methoxy-N,N-diisopropyltryptamine | 25 | no change. |
| 5-Methoxy-N,N-dimethyltryptamine | 25 | no change. |
| AB–CHMINACA | 15 | 30. |
| AB–FUBINACA | 50 | no change. |
| AB–PINACA | 15 | 30. |
| Acetyl Fentanyl | 100 | no change. |

| Basic class | Established 2017 quotas (g) | Proposed Revised 2017 quotas (g) |
|---|---|---|
| Acetyl-*alpha*-methylfentanyl | 2 | 30. |
| Acetyldihydrocodeine | 2 | 30. |
| Acetylmethadol | 2 | no change. |
| ADB–PINACA (*N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1*H*-indazole-3-carboxamide) | 50 | no change. |
| AH–7921 | 30 | no change. |
| Allylprodine | 2 | no change. |
| Alphacetylmethadol | 2 | no change. |
| *alpha*-Ethyltryptamine | 25 | no change. |
| Alphameprodine | 2 | no change. |
| Alphamethadol | 2 | no change. |
| *alpha*-Methylfentanyl | 2 | 30. |
| *alpha*-Methylthiofentanyl | 2 | 30. |
| *alpha*-Methyltryptamine (AMT) | 25 | no change. |
| *alpha*-Pyrrolidinobutiophenone ($\alpha$-PBP) | 25 | no change. |
| *alpha*-Pyrrolidinopentiophenone ($\alpha$-PVP) | 25 | no change. |
| Aminorex | 25 | no change. |
| APINCA, AKB48 (*N*-(1-adamantyl)-1-pentyl-1*H*-indazole-3-carboxamide) | 25 | no change. |
| Benzylmorphine | 2 | 30. |
| Betacetylmethadol | 2 | no change. |
| *beta*-Hydroxy-3-methylfentanyl | 2 | 30. |
| *beta*-Hydroxyfentanyl | 2 | 30. |
| *beta*-Hydroxythiofentanyl | 30 | no change. |
| Betameprodine | 2 | no change. |
| Betamethadol | 4 | no change. |
| Betaprodine | 2 | no change. |
| Bufotenine | 3 | no change. |
| Butylone | 25 | no change. |
| Butyryl fentanyl | 30 | no change. |
| Cathinone | 24 | no change. |
| Codeine methylbromide | 5 | 30. |
| Codeine-N-oxide | 305 | 330 |
| Desomorphine | 25 | no change. |
| Diethyltryptamine | 25 | no change. |
| Difenoxin | 8,750 | no change. |
| Dihydromorphine | 1,566,000 | no change. |
| Dimethyltryptamine | 35 | no change. |
| Dipipanone | 5 | no change. |
| Etorphine | Zero | 30. |
| Fenethylline | 5 | 30. |
| *gamma*-Hydroxybutyric acid | 56,200,000 | no change. |
| Heroin | 25 | 45. |
| Hydromorphinol | 2 | no change. |
| Hydroxypethidine | 2 | no change. |
| Ibogaine | 5 | 30. |
| JWH–018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) | 35 | no change. |
| JWH–019 (1-Hexyl-3-(1-naphthoyl)indole) | 45 | no change. |
| JWH–073 (1-Butyl-3-(1-naphthoyl)indole) | 45 | no change. |
| JWH–081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole) | 30 | no change. |
| JWH–122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) | 30 | no change. |
| JWH–200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) | 35 | no change. |
| JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) | 30 | no change. |
| JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) | 30 | no change. |
| JWH–398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) | 30 | no change. |
| Lysergic acid diethylamide (LSD) | 10 | 40. |
| MAB–CHMINACA; ADB–CHMINACA (*N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide). | Zero | 30. |
| Marihuana | 472,000 | no change. |
| Mecloqualone | Zero | 30. |
| Mescaline | 25 | no change. |
| Methaqualone | 10 | 60. |
| Methcathinone | 25 | no change. |
| Methyldesorphine | 5 | no change. |
| Methyldihydromorphine | 2 | no change. |
| Morphine methylbromide | 5 | no change. |
| Morphine methylsulfonate | 5 | no change. |
| Morphine-N-oxide | 350 | no change. |
| *N,N*-Dimethylamphetamine | 25 | no change. |
| Naphyrone | 25 | no change. |
| *N*-Ethyl-1-phenylcyclohexylamine | 5 | no change. |
| *N*-Ethylamphetamine | 24 | no change. |
| *N*-Hydroxy-3,4-methylenedioxyamphetamine | 24 | no change. |

| Basic class | Established 2017 quotas (g) | Proposed Revised 2017 quotas (g) |
|---|---|---|
| Noracymethadol | 2 | no change. |
| Norlevorphanol | 52 | 55. |
| Normethadone | 2 | no change. |
| Normorphine | 40 | no change. |
| Para-fluorofentanyl | 5 | 25. |
| Parahexyl | 5 | no change. |
| PB–22; QUPIC | 20 | no change. |
| Pentedrone | 25 | no change. |
| Pentylone | 25 | no change. |
| Phenomorphan | 2 | no change. |
| Pholcodine | 5 | no change. |
| Psilocybin | 30 | no change. |
| Psilocyn | 50 | no change. |
| SR–18 and RCS–8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) | 45 | no change. |
| SR–19 and RCS–4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) | 30 | no change. |
| Tetrahydrocannabinols | 409,000 | no change. |
| Thiofentanyl | 2 | 25. |
| THJ–2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) | 15 | 30. |
| Tilidine | 25 | no change. |
| Trimeperidine | 2 | no change. |
| UR–144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone | 25 | no change. |
| **Schedule II** | | |
| 1-Phenylcyclohexylamine | 4 | no change. |
| 1-Piperidinocyclohexanecarbonitrile | 4 | no change. |
| 4-Anilino-N-phenethyl-4-piperidine (ANPP) | 1,750,000 | no change. |
| Alfentanil | 4,200 | no change. |
| Alphaprodine | 2 | no change. |
| Amobarbital | 20,100 | no change. |
| Amphetamine (for conversion) | 12,000,000 | no change. |
| Amphetamine (for sale) | 42,400,000 | no change. |
| Carfentanil | 10 | 20. |
| Cocaine | 103,400 | no change. |
| Codeine (for conversion) | 40,000,000 | no change. |
| Codeine (for sale) | 45,000,000 | no change. |
| Dextropropoxyphene | 15 | 35. |
| Dihydrocodeine | 281,100 | 422,000. |
| Dihydroetorphine | 2 | no change. |
| Diphenoxylate (for conversion) | 15,000 | no change. |
| Diphenoxylate (for sale) | 820,000 | 1,110,000. |
| Ecgonine | 99,000 | no change. |
| Ethylmorphine | 2 | 30. |
| Etorphine hydrochloride | 32 | no change. |
| Fentanyl | 1,750,000 | no change. |
| Glutethimide | 2 | no change. |
| Hydrocodone (for conversion) | 122,000 | no change. |
| Hydrocodone (for sale) | 58,410,000 | no change. |
| Hydromorphone | 5,140,800 | no change. |
| Isomethadone | 4 | 30. |
| Levo-alphacetylmethadol (LAAM) | 3 | 5. |
| Levomethorphan | 10 | 30. |
| Levorphanol | 8,300 | 12,900. |
| Lisdexamfetamine | 19,000,000 | no change. |
| Meperidine | 3,706,000 | no change. |
| Meperidine Intermediate-A | 5 | no change. |
| Meperidine Intermediate-B | 9 | 30. |
| Meperidine Intermediate-C | 5 | no change. |
| Metazocine | 15 | no change. |
| Methadone (for sale) | 23,700,000 | no change. |
| Methadone Intermediate | 25,600,000 | no change. |
| Methamphetamine | 1,539,100 | no change. |
| [900,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 600,000 grams for methamphetamine mostly for conversion to a schedule III product; and 39,100 grams for methamphetamine (for sale)]. | | |
| Methylphenidate | 73,000,000 | no change. |
| Morphine (for conversion) | 27,300,000 | no change. |
| Morphine (for sale) | 41,000,000 | no change. |
| Nabilone | 19,000 | no change. |
| Noroxymorphone (for conversion) | 17,700,000 | no change. |
| Noroxymorphone (for sale) | 400,000 | no change. |

| Basic class | Established 2017 quotas (g) | Proposed Revised 2017 quotas (g) |
|---|---|---|
| Opium (powder) | 90,000 | no change. |
| Opium (tincture) | 907,200 | 600,000. |
| Oripavine | 22,000,000 | 22,700,000. |
| Oxycodone (for conversion) | 2,610,000 | no change. |
| Oxycodone (for sale) | 108,510,000 | no change. |
| Oxymorphone (for conversion) | 22,300,000 | no change. |
| Oxymorphone (for sale) | 4,200,000 | no change. |
| Pentobarbital | 27,500,000 | no change. |
| Phenazocine | 5 | no change. |
| Phencyclidine | 20 | 35. |
| Phenmetrazine | 2 | 25. |
| Phenylacetone | 20 | 40. |
| Racemethorphan | 2 | 5. |
| Racemorphan | 2 | 5. |
| Remifentanil | 3,000 | no change. |
| Secobarbital | 172,002 | no change. |
| Sufentanil | 4,000 | no change. |
| Tapentadol | 21,000,000 | no change. |
| Thebaine | 100,000,000 | no change. |
| **List I Chemicals** | | |
| Ephedrine (for conversion) | 50,000 | no change. |
| Ephedrine (for sale) | 5,360,000 | no change. |
| Phenylpropanolamine (for conversion) | 15,000,000 | no change. |
| Phenylpropanolamine (for sale) | 8,500,000 | no change. |
| Pseudoephedrine (for conversion) | 40 | no change. |
| Pseudoephedrine (for sale) | 200,00,000 | no change. |

The Acting Administrator further proposes that aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. In accordance with 21 CFR 1303.13 and 21 CFR 1315.13, upon consideration of the relevant factors, the Acting Administrator may adjust the 2017 aggregate production quotas and assessment of annual needs as needed.

## Conclusion

After consideration of any comments or objections, or after a hearing, if one is held, the Acting Administrator will issue and publish in the **Federal Register** a final order establishing any adjustment of 2017 aggregate production quota for each basic class of controlled substances in schedules I and II and established assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, 21 CFR 1303.13(c) and 1315.13(f).

Dated: July 27, 2017.

**Chuck Rosenberg,**

*Acting Administrator.*

[FR Doc. 2017–16440 Filed 8–3–17; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF LABOR

### Office of the Secretary

### Agency Information Collection Activities; Submission for OMB Review; Comment Request; Claim for Continuance of Compensation

**ACTION:** Notice of availability; request for comments.

**SUMMARY:** The Department of Labor (DOL) is submitting the Office of Workers' Compensation Programs (OWCP) sponsored information collection request (ICR) revision titled, ''Claim for Continuance of Compensation,'' to the Office of Management and Budget (OMB) for review and approval for use in accordance with the Paperwork Reduction Act (PRA) of 1995. Public comments on the ICR are invited.

**DATES:** The OMB will consider all written comments that agency receives on or before September 5, 2017.

**ADDRESSES:** A copy of this ICR with applicable supporting documentation; including a description of the likely respondents, proposed frequency of response, and estimated total burden may be obtained free of charge from the *RegInfo.gov* Web site at *http://www.reginfo.gov/public/do/PRAViewICR?ref_nbr=201703-1240-005* (this link will only become active on the day following publication of this notice) or by contacting Michel Smyth by telephone at 202–693–4129, TTY 202–693–8064, (these are not toll-free numbers) or sending an email to *DOL_PRA_PUBLIC@dol.gov.*

Submit comments about this request by mail or courier to the Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for DOL–OWCP, Office of Management and Budget, Room 10235, 725 17th Street NW., Washington, DC 20503; by Fax: 202–395–5806 (this is not a toll-free number); or by email: *OIRA_submission@omb.eop.gov.* Commenters are encouraged, but not required, to send a courtesy copy of any comments by mail or courier to the U.S. Department of Labor–OASAM, Office of the Chief Information Officer, Attn: Departmental Information Compliance Management Program, Room N1301, 200 Constitution Avenue NW., Washington, DC 20210; or by email: *DOL_PRA_PUBLIC@dol.gov.*

**FOR FURTHER INFORMATION CONTACT:** Michel Smyth by telephone at 202–693–4129, TTY 202–693–8064, (these are not toll-free numbers) or sending an email to *DOL_PRA_PUBLIC@dol.gov.*

**Authority:** 44 U.S.C. 3507(a)(1)(D).

**SUPPLEMENTARY INFORMATION:** This ICR seeks approval under the PRA for revisions to the Claim for Continuance of Compensation (Form CA–12)